Mobile website
Clinical Research
Curative efficacy of DC-CIK cells on the patients with advanced metastatic nasopharyngeal carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the curative efficacy of DC-CIK cells on the patients with advanced metastatic nasopharyngeal carcinoma. Methods: Twenty nine patients with advanced metastatic nasopharyngeal carcinoma treated with DC-CIK cells in Department of Tumor Biotherapy, the 81st Hospital of PLA during August 2011 to June 2015 were retrospectively analyzed. Changes of EB virus VCA-IgA antibody level and lymphocyte subsets before and after DC-CIK cells treatment, as well as its curative efficacy and safety were observed. Results: After the treatment with DC-CIK cells, the objective remission rate of the 29 patients was 0, disease control rate of the patients was 65.5%, media survival time of the patients was 42 months, and the 1-4 years survival rates were 68.0% for all. All the patients had no serious adverse reactions. EB virus VCA-IgA antibody in peripheral blood of the patients after the treatment was significantly lower than that before the treatment (\[30.88±3.91\] U/ml vs \[49.86±5.02\] U/ml, P<005). After the treatment with DC-CIK cells, CD8+ T cells numbers were obviously increased (P<0.05) with the ratio of CD4+/CD8+T significantly decreased (P<0.05). Conclusion: DC-CIK cells immunotherapy for the patients with advanced metastatic nasopharyngeal carcinoma might be safe and feasible, and could produce some clinical efficacy.
Keywords:
Project Supported:
Project supported by Program of Medical Science and Technology Innovation of Nanjing Military Area Command(No.14MS052)
Clc Number:
